Table 2

Incidence of the composite outcome (and its constituent events) according to the modality of cerebral cavernous malformation treatment

Cohorts (%)PatientsTotal number of outcome events/ Person-yearsMedian number per cohort (range)Outcome event incidence (95% CI) per 100 person-years
All cohortsFollow-up, person-years63 (100)342472 (1.7–1020)
Composite outcome*32 (51)1568313/51693 (0–108)6.1 (5.4–6.8)
 Deaths attributable to CCM or treatment63 (100)342428/100290 (0–4)0.3 (0.2–0.4)
 Deaths not attributed to CCM or treatment61 (97)322818/93480 (0–4)0.2 (0.1–0.3)
 Symptomatic ICH43 (68)2465160/83311 (0–32)1.9 (1.6–2.2)
 Persistent FND42 (67)2123201/62902 (0–82)3.2 (2.8–3.7)
Neurosurgery cohortsFollow-up, person-years49 (100)268448 (1.7–1020)
Composite outcome21 (43)1100198/30212 (0–108)6.6 (5.7–7.5)
 Deaths attributable to CCM or treatment49 (100)268418/67070 (0–4)0.3 (0.2–0.4)
 Deaths not attributed to CCM or treatment48 (98)26137/67010 (0–4)0.1 (0.05–0.2)
 Symptomatic ICH29 (59)172553/50081 (0–22)1.1 (0.8–1.4)
 Persistent FND31 (63)1655176/41432 (0–82)4.3 (3.7–4.9)
Stereotactic radiosurgery cohortsFollow-up, person-years14 (100)740160 (24.9–675)
Composite outcome11 (79)468115/21475 (1–35)5.4 (4.5–6.4)
 Deaths attributable to CCM or treatment14 (100)74010/33220 (0–2)0.3 (0.2–0.6)
 Deaths not attributed to CCM or treatment13 (93)61511/26470 (0–3)0.4 (0.2–0.8)
 Symptomatic ICH14 (100)740107/33225 (0–32)3.2 (2.7–3.9)
 Persistent FND11 (79)46825/21472 (0–6)1.2 (0.8–1.7)
  • *Composite outcome consisted of death, non-fatal symptomatic ICH or non-fatal new or worse non-haemorrhagic persistent FND attributed to CCM or its treatment.

  • CCM, cerebral cavernous malformation; ICH, intracranial haemorrhage; FND, focal neurological deficit; CI, confidence interval.